semaglutide cvd EFFECT OF THE GLP-1 RECEPTOR AGONIST ON TOTAL CARDIOVASCULAR EVENTS IN PATIENTS WITH CARDIOVASCULAR DISEASE AND OVERWEIGHT OR OBESITY BUT NO DIABETES IN THE SELECT TRIAL Semaglutide Shows Secondary Cardiovascular Prevention

Journal of Cosmetic Dermatology, 20 (12), 3759-3781

During sleep, antioxidant mechanisms take over to counteract the ROS accumulation and restore the cellular redox balance

GLP-1 medications mainly help manage blood sugar (glucose) levels in people with Type 2 diabetes, and, in some cases, can also help treat obesity

Both high and low blood pressure can be asymptomatic, making routine monitoring important for anyone taking semaglutide

8 weeks (~75 mg/day avg): ~9 vials 12 weeks: ~13 vials 16 weeks: ~17 vials Insulin Syringes (U-100, 1 mL) Per injection: 1 syringe 8 weeks (once daily): ~56 syringes 16 weeks (once daily): ~112 syringes Bacteriostatic Water (10 mL bottles) Use 5.0 mL per 500 mg vial for reconstitution